Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

HC Wainwright & Co. Downgrades Flexion Therapeutics to Neutral, Lowers Price Target to $10

Author: Benzinga Newsdesk | October 19, 2021 06:25am
HC Wainwright & Co. analyst Patrick Trucchio downgrades Flexion Therapeutics (NASDAQ:FLXN) from Buy to Neutral and lowers the price target from $25 to $10.

Posted In: FLXN